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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S217containing 50 % shells and 50% seeds (by weight) and the other version
containing 70% of shells and 30% of seeds (by weight). All animals 16
dogs and 16 horses were treated for a time period of three month, the
dose was 0.3 g pr kg daily, and data was lumped together. The human
studies also tested two different versions of the same shell and seed
containing Rose-hip remedy: The daily dose of one version was 1.2 g
seeds and a similar amount of shells (A version) and the daily dose of
the version (B) was 0.2 g seeds combined with 1.8 g shells.
The human study was performed in two groups of middle aged patients
with modest osteoarthritis. A seasonal variation is reported for CRP
(higher during winter), and both groups started treatment late autumn.
A number of 43 patients were given high dose seed version and 40 other
patients were given corresponding placebo. Another group of 32
patients (B group) were given the low seed version and corresponded to
30 patients on placebo. Data given are mean +/- SD. Wilcoxon test for
matched pairs was used within groups and Mann-Whitney when
comparing placebo and active treatment. A p level less than 0.050 was
regarded as statistically signiﬁcant.
Results: Treatment with the high seed level resulted in a statistically
signiﬁcant reduction in chemotaxis from 28.6 +/- 13.5 to 5.6 +/- 3.4 in
a group of eight animals (p<0.010). A modest and insigniﬁcant increase
was observed in a placebo group of identical magnitude, p <0.050
comparing the two groups. The low dose seed preparation, when tested
in another eight animals resulted in an insigniﬁcant 3% increase of
chemotaxis (p<0.830). No change in chemotaxis was observed in the
placebo group and therewere no signiﬁcant difference between groups.
Patients reaction to the high seed and low seed preparation supported
the observations from animal studies. Treated with the A version (1.2 g
seeds daily) resulted in a insigniﬁcant CRP reduction from 2.07 +/- 2.19
to 1.68 +/- 1.28 mg/l, a reduction of 18%. In the placebo group CRP levels
increased statistically signiﬁcant from 1,43 +/- 0.91 to 1.89 +/- 1.35 mg/l
(p<0.014) an increase which is most likely due to reported seasonal
variation. The two groups were signiﬁcantly different from each other
as indicated by a Mann-Whitney p value of 0.042. In the B group
receiving low dose seed treatment (0.2 g daily) there was a modest and
insigniﬁcant increase of 20% in CRP levels, which was not signiﬁcantly
different when compared to observations from the corresponding
placebo group (p<0.339).
Conclusion: The present data suggest that Rose-hip seeds are of
importance to keep the optimal anti-inﬂammatory proﬁle in Rose-hip
preparations.409
AN ORAL PREPARATION CONTAINING HYLAURONIC ACID
(ORALVISC) CAN NORMALIZE THE TURNOVER OF HYALURONIC
ACID IN SYNOVIAL FLUID OF OSTEOARTHRITIC KNEE PATIENTS
K.W. Li y, W. Wu z, C.L. Emson y, S.M. Turner y, R. Zvirbulis z, F. Nelson z, D.
Martinez-Puig x. yKineMed, Inc, Emeryville, CA, USA; zBone and Joint Ctr.,
Henry Ford Hosp., Detroit, MI, USA; xBioiberica S.A., Palafolls, Spain
Purpose: Osteoarthritis (OA) is a degenerative joint disease in which
articular cartilage matrix is no longer in homeostatic balance, resulting
in a net loss of chondroitin sulfate (CS)-rich glycosaminoglycans (GAGs).
The pro-inﬂammatory environment of synovial ﬂuid has been shown to
result in an increase in hyaluronic acid (HA) turnover. Consequently the
turnover of CS and HA are considered key parameters to evaluate the
degree and evolution of OA. We conducted a double blind randomized
clinical trial to determine if there would be changes in turnover of CS
and HA in the synovial ﬂuid (SF) of knee OA patients treated with
a patented hyaluronic acid formulation for oral use (Oralvisc) as
compared to placebo.
Methods: 51 symptomatic knee OA patients were recruited sequentially
at the time of an outpatient visit for OA. Subjects were between the ages
of 50-75 years, had knee effusion, and a pain visual analog score (VAS)
>50mm. 40 patients completed the study, 21 had been randomly
selected to receive 80 mg daily of Oralvisc, and the remaining 19 had
identical appearing placebos. Each month they were evaluated for VAS
and WOMAC pain and joint function. A subset of 10 subjects per
treatment group began a 2-day long oral administration of heavy water
(35 mL 2H2O TID for 2 days) at the conclusion of the treatment phase
(Week 12), followed by a synovial ﬂuid aspiration in the affected knee.
Synovial ﬂuid lavage samples were analyzed for 2H-labeling of
component GAGs by gas chromatography/ mass spectrometry (GC/MS)
to obtain fractional synthesis rates of HA and CS in SF.Results: The age, sex, race, BMI, KL scores, as well as VAS pain and
WOMAC function were balanced between groups at the beginning of
the trial. Treatment with oral HA during 3 months resulted in a signif-
icant improvement in VAS pain (p¼0.0035), WOMAC pain (p¼0.0259)
and WOMAC function (p¼0.0132) compared to placebo. The stable-
isotope-mass spectrometry method was successfully implemented for
the clinical study of SF GAG kinetics. The rate of HA turnover was
0.780.42 / day (i.e., 78% per day) in placebo-treated OA patients (n¼10;
Fig. 1). With 12 weeks of oral HA treatment, the mean rate of HA
turnover declined by 45% to 0.420.24 / day (p¼ 0.046). While we have
not directly compared the rate of HA turnover in normal vs. osteoar-
thritic knees, comparison of the current results with data from
a previous study in ACL patients suggests that these osteoarthritis
patients (0.78 / d) have elevated HA turnover relative to “normal”
subjects (0.25 / d), and that oral HA partially normalized the HA turn-
over rate. CS molecules in the SF were also highly enriched, with the
majority of the patients recording the maximum measureable turnover
rate for this assay (>140% / day). Thus, virtually all of the SF-derived CS
was recently synthesized, suggesting a defect in the retention of
potential repair molecules in osteoarthritic cartilage.
Conclusions: This is the ﬁrst study of its kind to show that the use of an
oral HA (Oralvisc) agent in knee OA patients can lead to a signiﬁcant
impact on HA turnover in synovial ﬂuid. The normalization in HA
turnover was paralleled by an overall decrease in pain scores and
improvement in joint function. Further studies are needed to investi-
gate its mechanism but this novel form of oral HA may provide a safe
alternative treatment to correct the homeostatic imbalances in the
progression of OA.
Figure 1. Turnover rate of HA in the knee synovial ﬂuid of osteoarthritic patients. Bar
shows the group mean (ANOVA p ¼ 0.046).
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SULFORAPHANE REPRESSES MATRIX-DEGRADING PROTEASES AND
PROTECTS CARTILAGE FROM DESTRUCTION IN VITRO AND IN VIVO
R.K. Davidson y, O. Jupp y, R. de Ferrars y, C.D. Kay y, K.L. Culley y, R.
Norton y, C. Driscoll z, T.L. Vincent z, S.T. Donell y, Y. Bao y, I.M.
Clark y. yUniv. of East Anglia, Norwich, United Kingdom; zKennedy Inst.
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Purpose: Broccoli is rich in glucoraphanin (a glucosinolate). When
broccoli is cut or chewed, glucoraphanin is converted by an enzyme,
myrosinase, to sulforaphane (an isothiocyanate). Similar compounds
are derived from other cruciferous vegetables and these compounds are
therefore accessible via the diet. Sulforaphane (SFN) has been reported
to regulate signalling pathways relevant to chronic diseases. Our study
investigated whether sulforaphane can abrogate cartilage destruction
in osteoarthritis and examined mechanism of action in chondrocytes.
Methods: The bovine nasal cartilage explant model (BNC) and desta-
bilisation of medial meniscus (DMM) murine model of osteoarthritis
were used to study chondroprotection by SFN. Histone acetylation, gene
expression, transcription factors nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) and nuclear factor kappaB (NF-kB) signalling were
examined.
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cartilage at the level of both proteoglycan and collagen breakdown
(10mM compared to cytokines alone). It also decreases arthritis score
in the DMM murine model of osteoarthritis (3mmol daily dose SFN in
diet versus control chow). SFN inhibited cytokine-induced metal-
loproteinase expression in primary human articular chondrocytes
(HACs) and in ﬁbroblast-like synovial cells (FLS). SFN acts indepen-
dently of the Nrf2 transcription factor and histone deacetylase activity
in HACs, but does mediate prolonged activation of Jun kinase (JNK) and
p38 MAP kinase. SFN attenuates NF-kB signalling through at least
inhibition of DNA binding in HACs with attenuation of expression of
several NF-kB dependent genes.
Conclusions: SFN, at levels which can be obtained through a high
broccoli diet, inhibits the expression of key metalloproteinases impli-
cated in osteoarthritis independently of Nrf2 and blocks inﬂammation
at the level of NF-kB to protect against cartilage destruction in vitro and
in vivo. Future studies in man will ascertain the potential of this
compound in human osteoarthritis.Fig 1. Extensor strength/weight in women (left) and men (right) without pain
(WOMAC ¼ 0, gray line) and those with severe pain (WOMAC>5, black line). Percent
differences are shown with 95% conﬁdence intervals.411
COLLAGEN METABOLISM OF HUMAN OSTEOARTHRITIC CARTILAGE
AS MODULATED BY COLLAGEN HYDROLYSATES
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Steinmeyer y. yUniv. of Giessen, Giessen, Germany; zRes. Inst. of
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Purpose: Collagen hydrolysates (CHs) are mixtures of collagen peptides
and are popular nutraceuticals used for prophylaxis of osteoarthritis
(OA). Collagen type I hydrolysates were found to stimulate the synthesis
of proteoglycans and collagen by cultured healthy bovine articular
chondrocytes [Oesser et al. 2003]. Recently a ligand-receptor interac-
tion of small collagen fragments with integrin domains were found
which might serve as a molecular mode of action of CHs [Siebert et al.
2010; Stoetzel et al. 2012].
The aim of our study was to determine for the ﬁrst time whether and to
what extent two commercially available CHs modulate 1) the synthesis
of collagen from human articular OA cartilage, and 2) the degradation of
collagen and proteoglycans from human OA cartilage obtained from
human knee joints.
Methods: CHs from porcine (Mobiforte, Astrid Twardy) and ﬁsh (FGH,
Peptan F 5000, Rousselot) origin were used for our experiments.
Peptides from CHs were chemically characterized using MALDI-TOF
mass spectrometry, Atom Force Microscopy (AFM) as well as Nuclear
Magnetic Resonance (NMR) spectroscopy.
The degree of OA changes was estimated according to Collins. In order
to determine the collagen synthesis, explants were radiolabeled with
[3H]-proline, washed several times, and radiolabeled again with [14C]-
proline in the presence of 0-10 mg/ml CHs [Goodwin et al. 2008].
Proteoglycans were determined by the DMMB-method, NO by the
Griess reaction, whereas MMP-1,-3,-13 and collagen type II within
media were measured using ELISA kits. Cell viability was evaluated
microscopically using ﬂuorescein diacetate and propidium iodide.
Untreated explants served as controls. Data presented are mean  SD
(n¼6). Groups of data were evaluated using ANOVA and the Friedman
test. Signiﬁcance was set to p < 0.05.
Results: MALDI-TOF and 2D-TOCSY NMR analysis revealed qualitative
differences between both CHs with respect to peptides identiﬁed in
each preparation, width of molecular weight distribution and the
average molecular weight.
Peptan F 5000 and Mobiforte did not modulate the collagen
synthesis. Only Mobiforte induced an increased loss of proteoglycans
from explants into nutrient media, whereas no loss of collagen was
observed. Signiﬁcantly elevated levels of NO, MMP-1, -3, -13 and/or
PGE2 were found for FGH and Mobiforte. CHs are not cytotoxic even
when tested at a high concentration of 10 mg/ml.
Conclusion: Our investigation shows for the ﬁrst time that CH prepa-
rations differ with respect to both the composition of peptides and their
biological activities on human chondrocytes. Thus, their biomedical
properties have to be studied thoroughly both in vitro and in animal as
well as clinical trials before being applied as safe and effective nutra-
ceuticals in patients.412
PAIN HAS A STRONGER ASSOCIATION WITH THIGH MUSCLE
STRENGTH THAN THE RADIOGRAPHIC STAGE OF KNEE
OSTEOARTHRITIS - DATA FROM THE OSTEOARTHRITIS INITIATIVE
A.S. Ruhdorfer y, W. Wirth y, W. Hitzl y, M.C. Nevitt z, F. Eckstein y. for the
OAI investigatorsy Paracelsus Med. Univ., Salzburg, Austria; zDept. of
Epidemiology and Biostatistics, Univ. of California, San Francisco, CA, USA
Purpose: Previous studies reported an association between reduced
(quadriceps) muscle strength and knee osteoarthritis (OA), but it
remains unclear to what extent this relationship depends on structural
(radiographic, i.e. rOA) status or pain. To disentangle the above relation,
we here study extensor and ﬂexor muscle strength across participants
with different radiographic OA stages, with and without pain, in a large
cohort of subjects with or at risk of knee OA.
Methods: Participants were drawn from the entire baseline incidence
and progression subcohort cohort of the Osteoarthritis Initiative (OAI;
n¼4674), including all right knees with central Kellgren-Lawrence
grade (KLG) readings and complete information on the WOMAC pain
score and measures of isometric muscle strength (n¼3809). Of these,
1378 were KLG0, 698 KLG1, 1054 KLG2, and 679 KLG3/4. In each KL
stratum, observations were stratiﬁed between WOMAC knee pain
scores: 0 (no pain), 1-5, and >5 (severe pain) [range 0-20], as the mean
was close to 5 in women and men. Measurements for maximum
isometric extensor and ﬂexor strength at 60 knee ﬂexion were taken
from the OAI database ("Good Strength Chair", Metitur Oy, Jyvaskyla,
Finland) and to account for inter-subject differences these were
normalized to body weight (strength/weight). Of the OAI healthy
reference cohort (KLG0, asymptomatic, and without OA risk factors),
only a small subset of (right) knees had strength measurements avai-
labale (13 women, 12 men), which were used for comparison. Separate
slopes ANCOVAmodels, with age as covariate and contrast analyses (for
age-adjustedmeans), were used to compare: a) limbs with severe vs. no
painwithin each KLG stratum b) painless limbs across KLG strata, and c)
painless limbs with rOA (KLG2-4) vs. healthy reference limbs.
Results: In bothmen andwomen, and across all KL grades, extensor and
ﬂexor strength/weight were signiﬁcantly and substantially less in
severely painful (WOMAC>5) than in painless limbs (Fig. 1); only ﬂexor
strength/weight in male KLG3/4 knees did not reach statistical signiﬁ-
cance (p¼0.08). In painless female limbs, extensor and ﬂexor strength/
weight differed signiﬁcantly between KL strata (p¼0.046/0.02). In male
limbs, extensor (but not ﬂexor) strength/weight differed between KL
strata (p<0.001). Although strength tended to be lower with higher KL
grades, painless KLG3/4 limbs displayed similar to greater strength than
KLG 0/1 limbs with severe pain (Fig.1). In women, extensor strength/
weight was by 10% [95%CI -19%,+39%) lower in painless rOA than in
healthy reference knees (n¼303 vs. 13); in men extensor strength/
weight was by 11% [95%CI -4%,+25%] lower in painless rOA than in
healthy reference knees (n¼238 vs. 12). However, these differences did
not reach statistical signiﬁcance (p¼0.50/0.15) and similar results were
found for ﬂexor strength/weight (p¼0.06/0.58).
Conclusion: Knee pain intensity is observed to be a very strong deter-
minant of muscle strength in men and women. A weak association
between radiographic stage (KLG) and muscle strength in painless
limbs is seen, particularly in women, but less so for ﬂexor strength in
men. Hence, pain appears to have a much stronger association with
thigh (and speciﬁcally quadriceps) muscle strength in knee OA than the
radiographic disease stage. Longitudinal studies need to show whether
